# Biovas

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biovas

- Industry: Medical Devices & Equipment
- Headquarters: Wuhan, China
- Website: www.biovas.com
- Latest round: Series A (Nov 3, 2015)
- Investors on record: 2

## About

Established in 2013 and based in Wuhan, China, Biovas is a medical company that specializes in the production, development and sales of medical devices, providing minimally invasive circulatory intervention devices. The company has a production and research base covering 3,600 square meters. Biovas has received ISO 13485 quality system certification and NMPA Class III interventional medical device GMP approval. It has been recognized as a pilot unit for intellectual property rights by the Ministry of Industry and Information Technology, designated as a National High-Tech Enterprise, and awarded titles such as Specialized, Fined, Peculiar and Innovative Small and Medium Enterprise, and Gazelle Enterprise. The company has also been part of the Wuhan East Lake 3551 Optics Valley Talent Program.

The company focuses on the development of medical devices for cardiovascular intervention, offering a comprehensive product line that includes coronary, peripheral, ENT (ear, nose, and throat), and respiratory interventional fields. The company's core technologies involve the processing of medical-use materials, high polymer materials, biodegradable materials, and drug-controlled release technologies. Biovas collaborates with several European and American medical device manufacturers and R&D institutions and has partnerships with over 50 authoritative clinical research centers across China for conducting clinical trials. The company holds 70 patents and has 19 product registration certificates, with more than 20 products in the process of type inspection or registration application.

The company generates revenue by selling a range of cardiovascular interventional devices, providing high-quality medical products and technical support services to the healthcare sector.

## Funding rounds

- Series A, Nov 3, 2015 — Rays Venture Capital
- Angel, Feb 6, 2015 — Tronfund

## Investors

- Tronfund (https://capitalatlas.ai/funds/tronfund) — Angel
- Rays Venture Capital (https://capitalatlas.ai/funds/rays-venture-capital) — Series A